There are currently 57 clinical trials in Lancaster, Pennsylvania looking for participants to engage in research studies. Trials are conducted at various facilities, including Lancaster General Hospital, Urological Associates Of Lancaster, Lancaster Urology and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
All
Ages:
All
Trial Updated:
02/12/2024
Locations: Not set, Lancaster, Pennsylvania
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates
IN.PACT™ AV Access Post-Approval Study (PAS002)
NCT04543539
Recruiting
Long-term safety will be summarized
Gender:
All
Ages:
21 years and above
Trial Updated:
02/12/2024
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Arteriovenous Fistula, Arteriovenous Fistula Stenosis, Arteriovenous Fistula Occlusion, Fistula
Register for Updates
Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
NCT05633602
Recruiting
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may in... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
02/06/2024
Locations: Lancaster General Ann B Barshinger Cancer Institute, Lancaster, Pennsylvania
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
A Randomized Trial to Evaluate Sequential vs Simultaneous Patching
NCT04378790
Recruiting
A randomized trial to determine whether simultaneous treatment with spectacles and patching has an equivalent VA outcome compared with sequential treatment, first with spectacles alone followed by patching (if needed), for previously untreated amblyopia in children 3 to <13 years of age.
Gender:
All
Ages:
Between 3 years and 13 years
Trial Updated:
02/05/2024
Locations: Conestoga Eye, Lancaster, Pennsylvania
Conditions: Amblyopia
Register for Updates
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
NCT02488967
Recruiting
This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whethe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/29/2024
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
Register for Updates
Assessment of Combined CCM and ICD Device in HFrEF
NCT05855135
Recruiting
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced le... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
01/19/2024
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction, Implantable Defibrillator User, CCM Therapy, Non-ischemic Cardiomyopathy, Ischemic Cardiomyopathy, Sudden Cardiac Arrest, Arrhythmias, Cardiac, Ventricular Tachycardia, Ventricular Fibrillation
Register for Updates
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
Recruiting
This clinical trial studies how well two surgical procedures (bilateral salpingectomy and bilateral salpingo-oophorectomy) work in reducing the risk of ovarian cancer for individuals with BRCA1 mutations. Bilateral salpingectomy involves the surgical removal of fallopian tubes, and bilateral salpingo-oophorectomy involves the surgical removal of both the fallopian tubes and ovaries. This study may help doctors determine if the two surgical procedures are nearly the same for ovarian cancer risk r... Read More
Gender:
Female
Ages:
Between 35 years and 50 years
Trial Updated:
01/12/2024
Locations: Lancaster General Ann B Barshinger Cancer Institute, Lancaster, Pennsylvania +1 locations
Conditions: Ovarian Carcinoma
Register for Updates
Ipilumumab and Nivolumab With or Without Hypofractionated Radiotherapy in Patients With Metastatic Melanoma
NCT03646617
Recruiting
The main purpose of this study is to determine the safety of combining ipilimumab and nivolumab with hypofractionated radiotherapy to a single tumor in patients with metastatic melanoma. Another purpose of this study is to determine the effect of ipilimumab, nivolumab and hypofractionated radiotherapy on the cancer as compared to ipilimumab and nivolumab.
Gender:
All
Ages:
18 years and above
Trial Updated:
01/04/2024
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Metastatic Melanoma
Register for Updates
Persona Revision Knee System Outcomes
NCT04821154
Recruiting
The study will evaluate the performance, clinical benefits and safety of the Persona Revision Knee System in patients who have received primary or revision total knee arthroplasty (TKA) treatment. This will be done using a multicenter, single-arm, consecutive series, retrospective cohort study with prospective follow-up.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/27/2023
Locations: Penn Medicine/ Lancaster General Health, Lancaster, Pennsylvania
Conditions: Arthroplasty Complications, Infection, Knee Disease, Knee Osteoarthritis
Register for Updates
Project Talk Trial: Engaging Underserved Communities in End-of-life Conversations
NCT04612738
Recruiting
Compared to the general population, individuals from underserved communities are more likely to receive low quality end-of-life care and unwanted, costly and burdensome treatments due in part to a lack of advance care planning (ACP; the process of discussing wishes for end-of-life care with loved ones/clinicians and documenting them in advance directives). This study will use existing, trusted, and respected social networks to evaluate two conversation-based tools intended to engage underserved... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/08/2023
Locations: Hospice and Community Care, Lancaster, Pennsylvania
Conditions: Advance Care Planning, Advance Directives, Terminal Illness, Chronic Illness, Communication
Register for Updates
Post-approval Study of Transcarotid Artery Revascularization in Standard Risk Patients With Significant Carotid Artery Disease
NCT05365490
Recruiting
The study objective is to evaluate real world usage of the ENROUTE Transcarotid Stent when used with the ENROUTE Transcarotid Neuroprotection System in patients at standard risk for adverse events from carotid endarterectomy
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
11/15/2023
Locations: Lancaster General Hospital, Lancaster, Pennsylvania
Conditions: Carotid Artery Diseases
Register for Updates
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy
NCT05112237
Recruiting
The objective of this study is to collect information on patients with cardiomyopathy (CM) due to mutations in the MYBPC3 gene, to evaluate their disease course, burden of illness, risk factors for this disease, and the quality of life (QoL). This study will also collect information on treatments, procedures and outcome in infants and children up to 18 yrs who have this mutation.
Gender:
All
Ages:
Between 0 years and 18 years
Trial Updated:
11/13/2023
Locations: Cardiology Care for Children, Lancaster, Pennsylvania
Conditions: Cardiomyopathy
Register for Updates